Resolutions of the Extraordinary General Meeting of Pharma Equity Group A/S
2 November 2023
Announcement no. 43
Resolutions of the Extraordinary General Meeting of Pharma Equity Group A/S
Pharma Equity Group A/S today held its Extraordinary General Meeting with the following results:
1) Attorney Martin Allan Christensen from Accura Advokatpartnerselskab was elected as chairman at the extraordinary general meeting.
2) The following new candidates were elected to the Board of Directors: (i) Omar S. Qandeel, and (ii) Martin Engell-Rossen.
The Board of Director immediately thereafter constituted itself with Christian Vinding Thomsen as the Chairman of the Board of Directors and Martin Engell-Rossen as the Vice Chairman of the Board of Directors.
The Board of Directors will thereafter consist of Christian Vinding Thomsen (Chairman), Martin Engell-Rossen (Vice Chairman), Omar S. Qandeel, Lars Gundorph and Peter Vilmann.
For further information, please contact:
Thomas Kaas Selsø, CEO of Pharma Equity Group A/S, phone: +45 40 22 21 14
Christian Vinding Thomsen, Chairman of the Board of Directors of Pharma Equity Group A/S, phone: +45 2622 7222
About Pharma Equity Group A/S
Pharma Equity Group, a listed company on the Nasdaq Copenhagen stock exchange, is fully dedicated to advancing the medical projects of its subsidiary, Reponex Pharmaceuticals A/S. With an unwavering focus on healthcare, Pharma Equity Group's primary objective is to bring significant value to Reponex Pharmaceuticals' medical projects.
The company is committed to providing extensive support, resources, and expertise to drive the development and success of these projects. As a strategic partner, Pharma Equity Group works closely with Reponex Pharmaceuticals, prioritizing the advancement of innovative medical solutions and breakthrough therapies. Every effort is currently directed towards ensuring the utmost success and impact of Reponex Pharmaceuticals' medical projects, with an unwavering dedication to improving global healthcare outcomes. Only when the full potential of Reponex Pharmaceuticals has been unfolded is the intention to explore opportunities to invest in other companies. This approach ensures a strong commitment to the current medical projects and their development, while – on the longer term – remaining open to new strategic investments for continuous growth.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Aktietilbagekøb i Sydbank – transaktioner i uge 4911.12.2023 10:12:24 CET | pressemeddelelse
Selskabsmeddelelse nr. 43/2023 Peberlyk 4 DK-6200 Aabenraa Telefon +45 74 37 37 37 Telefax +45 74 37 35 36 Sydbank A/S CVR-nr. DK 12626509, Aabenraa sydbank.dk 11. december 2023 Aktietilbagekøb i Sydbank – transaktioner i uge 49 Sydbank offentliggjorde den 6. juli 2023 et aktietilbagekøbsprogram på 600 mio. kr. Aktietilbagekøbsprogrammet startede den 10. juli 2023 og vil være afsluttet senest den 31. januar 2024. Aktietilbagekøbsprogrammet sker med henblik på nedsættelse af aktiekapitalen i Sydbank og gennemføres efter bestemmelserne i Europa-Parlamentets og Rådets forordning (EU) nr. 596/2014 af 16. april 2014 og EU Kommissionens delegerede forordning (EU) 2016/1052 af 8. marts 2016, samlet kaldet Safe Habour-reglerne. Under aktietilbagekøbsprogrammet er gennemført følgende transaktioner: Antal aktierGennemsnitlig købskursTransaktions-værdi (kr.)Akkumuleret seneste meddelelse 1.678.800 532.188.278,0004. december 2023 05. december 2023 06. december 2023 07. december 2023 08. december 2
Sydbank share buyback programme: transactions in week 4911.12.2023 10:12:24 CET | Press release
Company Announcement No 43/2023 Peberlyk 4 6200 Aabenraa Denmark Tel +45 74 37 37 37 Fax +45 74 37 35 36 Sydbank A/S CVR No DK 12626509, Aabenraa sydbank.dk 11 December 2023 Dear Sirs Sydbank share buyback programme: transactions in week 49 On 6 July 2023 Sydbank announced a share buyback programme of DKK 600m. The share buyback programme commenced on 10 July 2023 and will be completed by 31 January 2024. The purpose of the share buyback programme is to reduce the share capital of Sydbank and the programme is executed in compliance with the provisions of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 and Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, collectively referred to as the Safe Harbour rules. The following transactions have been made under the share buyback programme: Number of sharesVWAPGross value (DKK)Accumulated, most recent Announcement 1,678,800 532,188,278.0004 December 2023 05 December 2023 06 December 2023 0
Prepayments (CK93) - Totalkredit A/S11.12.2023 10:05:00 CET | Press release
To the Nasdaq Copenhagen Prepayments (CK93) Pursuant to s 24 of the Danish Capital Markets Act, Totalkredit A/S hereby publishes prepayment data (CK93) as at 08 December 2023 in the attached file. Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/. For further information about data format and contents, please refer to the Nasdaq website. Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21. Yours sincerely Totalkredit A/S Attachments Prepayments - Totalkredit A_S_11-12-2023eordindftk
Prepayments (CK93) - Nykredit Realkredit A/S11.12.2023 10:05:00 CET | Press release
To the Nasdaq Copenhagen Prepayments (CK93) Pursuant to s 24 of the Danish Capital Markets Act, Nykredit Realkredit A/S hereby publishes prepayment data (CK93) as at 08 December 2023 in the attached file. Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/. For further information about data format and contents, please refer to the Nasdaq website. Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21. Yours sincerely Nykredit Realkredit A/S Attachments Prepayments - Nykredit Realkredit A_S_11-12-2023eordindf
Ekstraordinære indfrielser (CK93) - Totalkredit A/S11.12.2023 10:05:00 CET | pressemeddelelse
Til Nasdaq Copenhagen Ekstraordinære indfrielser (CK93) I medfør af kapitalmarkedsloven § 24 offentliggør Totalkredit A/S hermed oplysninger om ekstraordinære indfrielser (CK93) pr. den 8. december 2023 i vedhæftede fil. Oplysningerne vil endvidere på sædvanlig måde blive formidlet via Nasdaq Copenhagen. Oplysningerne findes også i excel-format i Nykredits obligationsdatabase på https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/. For yderligere informationer om dataformat og -indhold henvises til Nasdaqs hjemmeside. Spørgsmål kan rettes til head of investor relations Morten Bækmand Nielsen på tlf. 44 55 15 21. Med venlig hilsen Totalkredit A/S Vedhæftede filer Ekstraordinære indfrielser - Totalkredit A_S_11-12-2023eordindftk